Literature DB >> 27115610

Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools.

Stefan Zimmerli1, Ralf Bialek2, Igor W Blau3, Andreas Christe4, Cornelia Lass-Flörl5, Elisabeth Presterl6.   

Abstract

We describe the case of a patient with a T-lymphoblastic lymphoma whose disseminated mucormycosis was diagnosed with delay, and we address the diagnostic and therapeutic decision-making process and review the diagnostic workup of patients with potential IFD. The diagnosis was delayed despite a suggestive radiological presentation of the patient's pulmonary lesion. The uncommon risk profile (T-lymphoblastic lymphoma, short neutropenic phases) wrongly led to a low level of suspicion. The diagnosis was also hampered by the lack of indirect markers for infections caused by Mucorales, the low sensitivity of both fungal culture and panfungal PCR, and the limited availability of species-specific PCR. A high level of suspicion of IFD is needed, and aggressive diagnostic procedures should be promptly initiated even in apparently low-risk patients with uncommon presentations. The extent of the analytical workup should be decided on a case-by-case base. Diagnostic tests such as the galactomannan and β-D-glucan test and/or PCR on biological material followed by sequencing should be chosen according to their availability and after evaluation of their specificity and sensitivity. In high-risk patients, preemptive therapy with a broad-spectrum mould-active antifungal agent should be started before definitive diagnostic findings become available.

Entities:  

Keywords:  Diagnosis; Emerging risk groups; Molecular biology; Mucorales; Mucormycosis

Mesh:

Substances:

Year:  2016        PMID: 27115610     DOI: 10.1007/s11046-016-0010-y

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  45 in total

Review 1.  Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO).

Authors:  M Ruhnke; A Böhme; D Buchheidt; O Cornely; K Donhuijsen; H Einsele; R Enzensberger; H Hebart; C P Heussel; M Horger; H Hof; M Karthaus; W Krüger; G Maschmeyer; O Penack; J Ritter; S Schwartz
Journal:  Ann Oncol       Date:  2011-09-23       Impact factor: 32.976

2.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).

Authors:  Georgios Chamilos; Mario Luna; Russell E Lewis; Gerald P Bodey; Roy Chemaly; Jeffrey J Tarrand; Amar Safdar; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Haematologica       Date:  2006-06-01       Impact factor: 9.941

3.  Rate of complications in immunocompromised patients and unexpectedly high proportion of zygomycetes in computed tomography-guided percutaneous lung biopsy specimens.

Authors:  Christian Garzoni; Philippe Dumont
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

4.  No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation.

Authors:  Hartmut Bertz; Kathrin Drognitz; Michael Lübbert
Journal:  Ann Hematol       Date:  2013-08-15       Impact factor: 3.673

5.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

Authors:  Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

Review 6.  The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts.

Authors:  Sarah P Georgiadou; Nikolaos V Sipsas; Edith M Marom; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

7.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update.

Authors:  J Maertens; O Marchetti; R Herbrecht; O A Cornely; U Flückiger; P Frêre; B Gachot; W J Heinz; C Lass-Flörl; P Ribaud; A Thiebaut; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2010-07-26       Impact factor: 5.483

8.  Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease.

Authors:  Sophia Koo; Julie M Bryar; John H Page; Lindsey R Baden; Francisco M Marty
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 10.  Patients at high risk of invasive fungal infections: when and how to treat.

Authors:  Maria J G T Rüping; Jörg J Vehreschild; Oliver A Cornely
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more
  1 in total

1.  The Curious Case of "Case Report" of Infections Caused by Human and Animal Fungal Pathogens: An Educational Tool, an Online Archive, or a Format in Need of Retooling.

Authors:  Jean-Philippe Bouchara; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2018-12       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.